Dr. Reddy's Laboratories Limited
All news and filings related to Dr. Reddy's Laboratories Limited.
View all news & filings- High impact
Dr. Reddy's Secures Health Canada Approval for Generic Semaglutide Injection
Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, becoming the first company to get marketing authorization. This enables commercialization, sale, and distribution in Canada, a key market for Semaglutide. The approval highlights Dr. Reddy's expertise in complex generics and peptide-based therapeutics.
Read the summary - Medium impact
Dr. Reddy's to Announce Q4 FY26 Results on May 12, 2026; Earnings Call Scheduled
Dr. Reddy's Laboratories will announce its Q4 and full year FY26 results on May 12, 2026. An earnings call is scheduled for the same day at 19:30 PM IST / 10:00 AM ET to discuss financial performance.
Read the summary - Low impact
Dr. Reddy's Laboratories Announces Loss of Share Certificates
Dr. Reddy's Laboratories Limited has reported the loss of share certificates. Shareholders have applied for duplicates. A public notice was published on April 23, 2026, in Business Standard and Nava Telangana. Claims must be lodged within 15 days at the Hyderabad office.
Read the summary - Medium impact
Dr. Reddy's Awaits Health Canada Approval for Semaglutide Injection
Dr. Reddy's Laboratories has not yet received Health Canada's 'Notice of Compliance' for its Semaglutide Injection. The company received 'Drug Identification Numbers' on April 22, 2026, and continues to engage with regulators for market launch approval. No negotiations are ongoing, and no material impact is foreseen.
Read the summary - Medium impact
Dr. Reddy's Awaiting Health Canada Approval for Semaglutide Injection
Dr. Reddy's Laboratories confirmed it has not yet received Health Canada approval for its Semaglutide Injection. The company received Drug Identification Numbers (DINs) on April 22, 2026, and is awaiting regulatory clearance to launch the product in Canada.
Read the summary - Medium impact
Dr. Reddy's Board Meeting on April 24 to Consider Final Dividend for FY26
Dr. Reddy's Laboratories Limited's Board will meet on April 24, 2026, to consider recommending a final dividend for FY 2025-26. This follows a previous intimation on March 23, 2026.
Read the summary - Low impact
Dr. Reddy's Russia Subsidiary Receives Final Tax Penalty Decision of RUB 9.27 Million
Dr. Reddy's Russian subsidiary received a final tax penalty decision of RUB 9.27 million (INR 11.40 million) from the Russian Federal Tax Service. The penalty relates to VAT on marketing services. The company states this has no material financial impact.
Read the summary - Low impact
Dr. Reddy's Labs Files SEBI Compliance Certificate for Q4 FY26
Dr. Reddy's Laboratories Limited has submitted a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The certificate from Bigshare Services Private Limited confirms processing of dematerialized securities and updates to the register of members.
Read the summary - Low impact
Dr. Reddy's Sells Entire Stake in Wholly Owned Subsidiary Svaas Wellness Limited for ₹2.23 Crore
Dr. Reddy's Laboratories has sold its entire stake in wholly owned subsidiary Svaas Wellness Limited for ₹2.23 Crore. Svaas Wellness had a turnover of ₹28.5 Crore in FY25, representing 0.09% of Dr. Reddy's consolidated turnover. The buyer, Enspirit Technology Services Private Limited, is not a related party.
Read the summary - Low impact
Dr. Reddy's Allots 3,675 Equity Shares Under ESOP Scheme
Dr. Reddy's Laboratories allotted 3,675 equity shares on March 26, 2026, under its ESOP scheme. The issuance was to eligible employees exercising stock options. This increases the total issued shares to 83,46,57,970.
Read the summary - Low impact
Dr. Reddy's Laboratories Amends Fair Disclosure Code
Dr. Reddy's Laboratories amended its 'Code of Practices and Procedures for Fair Disclosures of Unpublished Price Sensitive Information' on March 24, 2026. The revised code ensures uniform dissemination of UPSI and compliance with SEBI PIT Regulations.
Read the summary - Medium impact
Dr. Reddy's Board Meeting on May 12, 2026, to Review FY26 Financial Results; Trading Window Closed
Dr. Reddy's Board will meet on May 12, 2026, to approve audited standalone and consolidated financial results for Q4FY26 and FY26. The trading window for securities will be closed from March 25, 2026, to May 14, 2026.
Read the summary - High impact
Dr. Reddy's Launches India's First DCGI-Approved Semaglutide Injection 'Obeda®' for Type 2 Diabetes
Dr. Reddy's launched 'Obeda®', India's first DCGI-approved generic semaglutide injection for Type 2 Diabetes. It demonstrated non-inferior efficacy and safety in Phase III trials. Available in 2mg and 4mg strengths at ₹4,200/month, it aims to improve access to advanced therapies.
Read the summary - Low impact
Dr. Reddy's Receives GST Orders for ₹2.2 Crore Penalties for FY19-22
Dr. Reddy's Laboratories received GST orders demanding ₹2,19,48,944 for FY19-20, ₹50,406 for FY20-21, and ₹4,384 for FY21-22, totaling approximately ₹2.2 crore in penalties. The company believes there is no material impact on its financials and is evaluating an appeal.
Read the summary - Medium impact
Dr. Reddy's Subsidiary's Lung Cancer Trial Halted Due to Futility
Dr. Reddy's subsidiary's Phase III trial for Eftilagimod Alfa in lung cancer patients has been recommended for discontinuation by the IDMC due to futility. Enrollment is halted, and an orderly wind-down is underway. Dr. Reddy's SA has made an upfront payment.
Read the summary - Low impact
Dr. Reddy's Announces Special Window for Physical Share Transfer Re-lodgement
Dr. Reddy's Laboratories opens a special window from Feb 5, 2026, to Feb 4, 2027, for re-lodging physical share transfer requests rejected before April 1, 2019. Transferred shares will be in demat and locked in for one year.
Read the summary - Low impact
Dr. Reddy's Allots 10,275 Shares Under ESOPs on March 12, 2026
Dr. Reddy's Laboratories allotted 10,275 equity shares on March 12, 2026, under its ESOP schemes. This issuance brings the total issued shares to 83,46,54,295, with a total issued share capital of ₹83,46,54,295.
Read the summary - Medium impact
Dr. Reddy's Allowed to Manufacture Semaglutide for Export by Delhi High Court
Dr. Reddy's has been permitted by the Delhi High Court to manufacture Semaglutide for export. The court upheld a prior order, allowing manufacturing and export to countries without Novo Nordisk's patent registration. The matter remains sub-judice.
Read the summary - Medium impact
Dr. Reddy's Appoints M S Madhu Sundar as Global Head of Quality and PV, Effective April 1, 2026
Dr. Reddy's Laboratories appoints M S Madhu Sundar as Global Head of Quality and PV, effective April 1, 2026. Sundar, with 28 years of experience, will also join the Management Council. Other senior management role changes, including CEO Global Generics and COO, are also effective April 1, 2026.
Read the summary - Medium impact
Dr. Reddy's Laboratories: US DOJ Closes FCPA Inquiry Without Enforcement Action
Dr. Reddy's Laboratories has been notified by the U.S. Department of Justice that its inquiry into potential Foreign Corrupt Practices Act violations has been closed without recommended enforcement action. This follows a similar closure of the SEC's investigation. The company had previously disclosed an investigation into allegations of improper payments to healthcare professionals.
Read the summary - Low impact
Dr. Reddy's Srikakulam Facility Inspection Closed by USFDA with VAI Classification
Dr. Reddy's Laboratories received the Establishment Inspection Report (EIR) from the USFDA for its Srikakulam facility. The inspection, previously disclosed on December 12, 2025, has been classified as 'Voluntary Action Indicated (VAI)' and is officially closed.
Read the summary - Low impact
Dr. Reddy's to Participate in Investor Meetings with Ambit Capital and Goldman Sachs in March 2026
Dr. Reddy's Laboratories will participate in investor meetings on March 4, 2026, with Ambit Capital in Hyderabad and on March 5, 2026, with Goldman Sachs virtually. These meetings are scheduled to discuss company matters with institutional investors.
Read the summary - Medium impact
Dr. Reddy's Laboratories Secures Favorable Outcome in SEC Investigation
Dr. Reddy's Laboratories received a letter from the SEC on February 23, 2026. The SEC has concluded its investigation into allegations of improper payments and does not intend to recommend enforcement action against the company at this time. The company fully cooperated with the SEC and DOJ.
Read the summary - Medium impact
Dr. Reddy's Acquires Progynova®, Cyclo-Progynova® Trademarks in India for ₹828 Crore
Dr. Reddy's Laboratories acquired Progynova® and Cyclo-Progynova® trademarks and related assets in India from Mercury Pharma Group Limited for USD 32.15 million (approximately ₹267.76 crore). This move strengthens Dr. Reddy's gynecology portfolio and marks its entry into the Hormone Replacement Therapy segment.
Read the summary - Low impact
Dr. Reddy's Allots 12,665 Equity Shares Under ESOP Schemes
Dr. Reddy's Laboratories allotted 12,665 equity shares on February 17, 2026, under its ESOP schemes. These shares were exercised at various prices including Re.1/-, Rs. 735.80/-, and Rs. 521.40/-. Post-allotment, the company's total issued shares are 83,46,44,020.
Read the summary - Low impact
Dr. Reddy's Laboratories: Notice of Loss of Share Certificates Published
Dr. Reddy's Laboratories published a notice on February 12, 2026, regarding lost share certificates. Shareholders must lodge claims within 15 days. Separately, SEBI's special window for dematerialising physical securities is open from February 5, 2026, to February 4, 2027.
Read the summary - Low impact
Dr. Reddy's to Participate in Kotak Institutional Equities Investor Meet on Feb 23, 2026
Dr. Reddy's Laboratories Limited will participate in an investor meet organized by Kotak Institutional Equities. The in-person group meeting is scheduled for February 23, 2026, in Mumbai. The company's management will engage with institutional investors during this event.
Read the summary - Low impact
Dr. Reddy's Laboratories: Mr. Sushrut Kulkarni Resigns as Global Head of IPDO
Mr. Sushrut Kulkarni has resigned as Global Head of IPDO and Senior Management Personnel at Dr. Reddy's Laboratories. His cessation from employment and the role is effective May 8, 2026, as he seeks opportunities outside the company.
Read the summary - Low impact
Dr. Reddy's Labs to Participate in Nuvama Investor Meet on Feb 9, 2026
Dr. Reddy's Laboratories management will attend an investor conference organized by Nuvama in Mumbai. The group meet is scheduled for February 9, 2026. The schedule is subject to change.
Read the summary - Medium impact
Dr. Reddy's Q3FY26 Earnings Call Transcript Released
Dr. Reddy's Q3FY26 revenues grew 4.4% YoY to ₹8,727 crores, with underlying EBITDA margin at 24.8% (adjusted for a one-time provision). The India business grew 19% YoY. Semaglutide received Indian marketing authorization, with Canada launch expected Feb-May 2026. Denosumab biosimilar approved in EU/UK, but received USFDA CRL.
Read the summary - Low impact
Dr. Reddy's Russia Subsidiary Receives Tax Audit Decision, Penalty of Rub 20.09 Mn
Dr. Reddy's Russian subsidiary received a tax audit decision on January 23, 2026. A penalty of Rub 20.09 million (INR 24.50 million) has been levied for alleged re-classification of marketing services as taxable. The company believes there is no material financial impact.
Read the summary - High impact
Dr. Reddy's Labs Q3 FY26 Results: Total Income at ₹15,148 Crore, Net Profit ₹2,043 Crore
Dr. Reddy's Laboratories reported Q3 FY26 consolidated results. Total income for nine months reached ₹15,148 crore, with net profit after tax at ₹1,529 crore. For the quarter, total income was ₹5,398 crore and net profit after tax was ₹579 crore. The Board recommended an interim dividend of ₹20 per share.
Read the summary - Low impact
Dr. Reddy's Laboratories Q3 FY26 Earnings Call Audio Recording Available
Dr. Reddy's Laboratories has released the audio recording of their earnings call held on January 21, 2026. The call discussed results for the quarter ended December 31, 2025. The recording is available via a provided weblink.
Read the summary - Medium impact
Dr. Reddy's Q3 FY26 Revenue at ₹8,727 Cr, Up 4.4% YoY
Dr. Reddy's reported Q3 FY26 consolidated revenue of ₹8,727 crore, a 4.4% YoY increase. EBITDA was ₹2,049 crore (up 11% YoY), and PAT was ₹1,210 crore (up 14% YoY). The company highlighted strategic collaborations, new product launches like Hevaxin®, and a commitment to Net Zero Climate Targets by FY2045.
Read the summary - Medium impact
Dr. Reddy's Q3FY26 Revenues at ₹87,268 Mn, Profit Attributable to Equity Holders at ₹12,098 Mn
Dr. Reddy's Laboratories reported Q3FY26 consolidated revenues of ₹87,268 million, up 4.4% YoY. Profit attributable to equity holders was ₹12,098 million, down 14% YoY. Key developments include a strategic collaboration with Immutep and new drug launches in India. The company also announced Science-Based Net Zero Climate Targets.
Read the summary - Medium impact
Dr. Reddy's Launches Generic Olopatadine HCl Ophthalmic Solution OTC in US
Dr. Reddy's Laboratories launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once-Daily Relief, in the U.S. This expands their OTC eye-care portfolio. The Pataday® brand had U.S. sales of approximately $69.9 million (₹582.7 crore) in the latest 52-week period.
Read the summary - Medium impact
Dr. Reddy's Receives USFDA Post-Application Action Letter for Hyderabad Facility
Dr. Reddy's Laboratories received a Post-Application Action Letter (PAAL) from the USFDA for its Hyderabad biologics manufacturing facility. This follows a Pre-Approval Inspection (PAI). The company is committed to addressing the USFDA's queries.
Read the summary - Medium impact
Dr. Reddy's to Announce Q3FY26 Results on Jan 21, 2026; Earnings Call Scheduled
Dr. Reddy's Laboratories will announce its Q3FY26 results on January 21, 2026. An earnings call is scheduled for the same day at 19:30 IST / 9:00 AM ET to discuss financial performance. Results will be released after the Board Meeting.
Read the summary - Low impact
Dr. Reddy's Labs: Certificate under SEBI Depositories Regs for Q3FY26
Dr. Reddy's Laboratories Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018. The confirmation certificate is from the Registrar and Share Transfer Agent for the quarter ended December 31, 2025.
Read the summary - Low impact
Dr. Reddy's Laboratories: Notice of Loss of Share Certificates
Dr. Reddy's Laboratories Limited announced a notice regarding lost share certificates. Shareholders have applied for duplicate certificates. The public is cautioned against dealing with these lost certificates. Claims must be lodged within 15 days of publication, after which duplicates will be issued.
Read the summary - Low impact
Dr. Reddy's Receives GST Demand Orders Totaling ₹8.4 Cr with Penalty
Dr. Reddy's Laboratories received GST demand and penalty orders totaling ₹8.4 crore for FY19-FY23 due to alleged excess input tax credit. The company believes there is no material financial impact and is considering an appeal.
Read the summary - Medium impact
Dr. Reddy's Swiss Receives Complete Response Letter from USFDA for AVT03
Dr. Reddy's Swiss subsidiary received a Complete Response Letter from USFDA for its BLA for AVT03, a biosimilar candidate. The CRL is related to observations from a pre-license inspection of Alvotech's manufacturing facility.
Read the summary - Medium impact
Dr. Reddy's Board Meeting Jan 21 to Approve Q3 FY26 Results; Trading Window Closed
Dr. Reddy's Laboratories will hold a Board meeting on January 21, 2026, to approve Q3 FY26 unaudited standalone and consolidated financial results. The trading window for securities will be closed from December 25, 2025, to January 23, 2026.
Read the summary - Low impact
Dr. Reddy's Laboratories: Newspaper Publication on Loss of Share Certificates
Dr. Reddy's Laboratories published a notice regarding lost share certificates. The notice appeared in Business Standard and Nava Telangana on December 17, 2025. This is for the information and records of the stock exchanges.
Read the summary - Low impact
Dr. Reddy's to Participate in Investec Group Meet on Dec 22
Dr. Reddy's Laboratories will participate in an investor group meet organized by Investec. The meeting is scheduled to be held in Chennai on December 22, 2025, from 10:00 to 17:00 IST. This is part of the company's engagement with institutional investors.
Read the summary - Medium impact
Dr. Reddy's Srikakulam Facility Receives 5 Observations from USFDA Inspection
Dr. Reddy's Srikakulam facility underwent a USFDA GMP and PAI inspection from December 4-12, 2025. The inspection resulted in 5 observations on a Form 483. The company plans to address these within the stipulated timeline.
Read the summary - Low impact
Dr. Reddy's Management to Participate in Investor Meetings from Dec 17
Dr. Reddy's Laboratories management will attend investor meetings. A group meet with B&K Securities is scheduled for December 17, 2025, in Hyderabad, from 10:30 AM to 11:30 AM IST. The schedule is subject to change.
Read the summary - Medium impact
Dr. Reddy's Sets Net Zero Targets: 80% Scope 1 & 2 GHG Cut by FY2030
Dr. Reddy's Laboratories commits to Net Zero greenhouse gas emissions by FY2045. Near-term targets include an 80% reduction in Scope 1 & 2 emissions and a 51.6% reduction in Scope 3 emissions by FY2030 (vs. FY2023 baseline). The company is also on track for coal- and furnace oil-free operations by FY'26.
Read the summary - Low impact
DRREDDY: Allotment of Equity Shares on exercise of Stock Options under ESOPs
Dr. Reddy's Laboratories allotted 9,165 equity shares to employees on December 9, 2025, under its ESOP schemes, resulting in a total issued share capital of ₹83,46,31,355.
Read the summary - Medium impact
Dr. Reddy's enters licensing agreement with Immutep for Eftilagimod Alfa
Dr. Reddy's collaborates with Immutep for Eftilagimod Alfa, gaining exclusive rights outside key markets. Immutep receives USD 20 million upfront with potential for USD 349.5 million in milestones plus royalties.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio